Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 前列腺癌前列腺癌
展开 前列腺癌流行病学前列腺癌流行病学
展开 前列腺癌的诊断前列腺癌的诊断
折叠 前列腺癌的治疗前列腺癌的治疗
展开 延期治疗延期治疗
展开 外科手术外科手术
展开 放射疗法放射疗法
展开 冷冻疗法冷冻疗法
展开 激素疗法激素疗法
展开 化疗化疗
展开 去势抵抗性前列腺癌(CRPC)去势抵抗性前列腺癌(CRPC)
展开 转移性前列腺癌转移性前列腺癌
折叠 其他治疗方式其他治疗方式
展开 老年男性前列腺癌的治疗老年男性前列腺癌的治疗
展开 局部前列腺癌除手术和放疗以外的其他初级治疗选择局部前列腺癌除手术和放疗以外的其他初级治疗选择
展开 局部前列腺癌患者的治疗后生活质量局部前列腺癌患者的治疗后生活质量
展开 根治性目的治疗后仅限PSA复发的治疗根治性目的治疗后仅限PSA复发的治疗
局部前列腺癌患者的治疗后生活质量
Preferred Name Post-treatment quality of life in patients with localised prostate cancer
Definition Increased life expectancy in PCa makes post-treatment QoL a key issue. Health-related QoL (HRQoL) refers to the impact of disease and treatment on well-being and physical, emotional and social functioning, including daily functioning. HRQoL is rated by patients, and is important because physicians often underestimate the impact of disease and treatment on patients. PCa-specific HRQoL refers to the disease-specific outcome of PCa, including urinary, bowel and sexual functioning. General HRQoL refers to well-being, vitality, fatigue, pain, general health status, global QoL, and life satisfaction. HRQoL is measured using standardised questionnaires, which provide an objective assessment of general and disease-specific domains. Comparison of the most common contemporary therapies for localised PCa is necessary to inform patients about treatment options and address patient preferences for the various possible outcomes. There is still limited objective data about HRQoL in PCa treatment.
Synonyms & Abbreviations Post-treatment quality of life in patients with localised prostate cancer
ReferenceCode NA
ReferenceURL NA
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.